IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re-Atsutoshi IKESUE et al.

Application No.: 10/557.611

Filed: November 22, 2005

Confirmation No.: 1480

Group Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

Attorney Docket No : 7388/84495

Customer No.: 42798

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Customer Service Window Randolph Building 401 Dulany Street Alexandria, VA 22314

Sir:

Pursuant to 37 CFR 1.97 and 1.98, the references listed on the enclosed Form PTO/SB/08 are submitted for consideration by the Examiner in the examination of the above-identified patent application.

The full consideration of the references in their entirety by the Examiner is respectfully requested and encouraged. Also, it is respectfully requested that the references be entered into the record of the present application and that the Examiner place his or her initials in the appropriate area on the enclosed Form PTO/SB/08, thereby indicating the Examiner's consideration of each of the references.

The submission of the references listed on the Form PTO/SB/08 is for the purpose of providing a complete record and is not a concession that the references listed thereon are prior art to the invention claimed in the patent application. The right is expressly reserved to establish an invention date earlier than the above-identified filing date in order to remove any reference submitted herewith as prior art should it be deemed appropriate to do so.

Further, the submission of the references is not to be taken as a concession that any reference represents art that is relevant or analogous to the claimed invention. Accordingly, the right to argue that any reference is not properly within the scope of prior art relevant to an examination of the claims in the above-identified application is also expressly reserved.

The Information Disclosure Statement is being filed:

(X) within any one of the following time periods: (a) within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d); (b) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 of an international application; (c) before the mailing date of a first Office Action on the merits; or (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

- () after (a), (b), (c) or (d) above, but before the mailing date of a final action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and includes *one* of:
 - the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below).

or

- () the fee of \$180 set forth in 37 CFR 1.17(p) (see "Fees" below).
- () after the mailing date of a final action under 37 CFR 1.113 or a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and on or before payment of the issue fee, and includes the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below).
- () after the mailing date of a Notice of Allowance under 37 CFR 1.311, and on or before payment of the issue fee, and within thirty days of receiving each item of information contained in the Information Disclosure Statement, and includes the Statement under 37 CFR 1.704(d) (see "Statement under 37 CFR 1.704(d)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below).

NOTE: This is for original applications except applications for a design patent, filed on or after May 29, 2000, wherein a paper containing only an Information Disclosure Statement in compliance with 37 CFR 1.97 and 1.98 is being filed.

Copies of the References

- (X) Copies of the references listed on the enclosed Form SB/08 are enclosed herewith.
- (X) A copy of the International Search Report is enclosed herewith.
- () A copy of the Supplementary European Search Report is enclosed herewith.
- () The references listed on the enclosed Form PTO/SB/08 were previously identified in the parent application(s) of the present application, and copies of the references were furnished at that time. Accordingly, additional copies of the references are not submitted herewith, so as not to burden the file with duplicate copies of references. The Examiner is respectfully requested to carefully review the references in accordance with the requirements set out in the Manual of Patent Examining Procedure. In accordance with 37 CFR 1.98(d), the details of the parent application(s) relied upon for an earlier filing.

date under 35 USC 120 in which copies of the references were previously furnished are set out below:

U.S. APPLI	CATIONS	Status (check one)				
U.S. APPLICATIONS	U.S. FILING DATE	PATENTED	PENDING	ABANDONED		
1.						
2.						
3.						

Statement under 37 CFR 1.97(e)

- () The undersigned hereby states that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.
- () The undersigned hereby states that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

Statement under 37 CFR 1.704(d)

() The undersigned hereby states that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 CFR 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement

Fees

- (X) No fee is owed by the applicant(s).
- () The IDS Fee of \$180 under 37 CFR 1.17(p) is enclosed herewith.

Method of Payment of Fees

- () Attached is a check in the amount of \$180.00.
- Charge Deposit Account No. 06-1135, under Order No., in the amount of \$0.00. (A duplicate copy of this communication is enclosed for that purpose.)

Authorization to Charge Additional Fees

(X) If any additional fees are owed in connection with this communication, please charge Deposit Account No. 06-1135. (A duplicate copy of this communication is enclosed for that purpose.)

Instructions as to Overpayment

- (X) Credit Account No. 06-1135.
- () Refund

Respectfully submitted,

FITCH, EVEN, TABIN & FLANNERY

weth Cla

Date: December 8, 2005

Kendrew H. Colton Registration No. 30,368

OFFICIAL CORRESPONDENCE TO Customer No. 42798

FITCH, EVEN, TABIN & FLANNERY 1801 K Street, NW, Suite 401L Washington, DC 20006

Tel: (202) 419-7000 Fax: (202) 419-7007

	PTO/SB/0			Application Number			10/557,611			
Substitute for Form 1449A/PTO					Filing Dat	e	November 2		2005	
			TION DISCLOSURE	First Named Inventor						
	STATEMENT BY APPLICANT (Use as many sheets as necessary) Sheet 1 of 2				Art Unit		Not Yet Assigned			
					Examiner	Not Yet Assigned				
					Attorney	Docket	7388/84495			
	U.S. PA	TEN	T DOCUMENTS							
	Examiner	xaminer Cite Document Number		Publication Date			f Patentee or		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	Bright.	No.¹	No.1 Number-Kind Code ²		1-DD-YYYY	DD-YYYY Applicant of C		t		
	1 ' N	US-5,883,106		03-16-1999		Stevens				
7	2005 3		US-5,856,345		05-1999	Doi et al.				
ĺ			US-6,063,928		05-16-2000 Stevens		al.			
	WQ.	US-6,239,285 B1		05-29-2001 Norris		Norris et al.	s et al.			
			US-							
ı			US-							
		US- US-								
			US-							
			US-							
		US- US-								
	FOREIGN	N PA	TENT DOCUMENTS							Γ
		Cite No.1			blication Date			Pages, Columns, Lines, Where Relevant Passages		т.
l	Initials*		Country Code ³ -Number ⁴ -Kind Code ⁵	M	M-DD-YYYY	Applicant of Cited Document		or Relevant Figures App		Ľ
			JP 60-155111 A	08-15-1985		Hisamitsu Pharm Co		Abstract		
ı		JP 09-169658 A JP 2002-104922 A		06	6-30-1997	Pola Chem	m Ind Inc		Abstract	
ı				04	1-10-2002	Beiersdorf /	sdorf AG		Abstract	
ı			EP 1146111 A1		0-17-2001	The Procter & Gamble		L		
ı		_	WO 02/102376 A1	12	2-27-2002	Pharmacia (Corp	L		L
Į		_	JP 08-283150 A		0-29-1996	Kao Corp		Abstract		L
l		_	JP 2001-106686 A	04	1-17-2001	Pfizer Prod	Pfizer Prod Inc			
		JP 08-104636 A		04	1-23-1996	Senju Pharr	Pharm Co		Abstract	
I		JP 07-304670 A		11	1-21-1995	Senju Pharr	n Co	AŁ	stract	Ĺ
I		_	WO 02/07698 A2	01	1-31-2002	Basf Antien	ngesellschaft At		Abstract	
I		_	JP 2002-128701	OE	5-09-2002	Sankyo Co	Ltd Ab		Abstract	
ĺ				1						1

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if

Date

Considered

Examiner

Signature

*EXAMINENT: Initial if efference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if no in conformance and not considered, include copy of this form with next communication to applicant.

MEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO) stem to Capil. *For Japanese patient documents, the indication of the year of the reign of the Emperor must precede the serial number of the patient ment. *Kind document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here it English language Translation is attached.

	PTO/SB/G		orm 1449A/	(DTO		Application Number	10/557,611						
	Substitut	101 1	OIII 1443A)	-10		Filing Date	November 22, 2005						
			TION DI			First Named Inventor	Atsutoshi IKESUE						
	STAT	EME	NT BY A	APPL	ICANT	Art Unit	Not Yet Assigned						
	(Use as n	(Use as many sheets as necessary)			1	Examiner Name	Not Yet Assigned						
	Sheet		2 of 2			Attorney Docket	7388/84495						
	NON PA	ATEN	T LITERATURE DOCUMENTS										
OIPE	Examine	Cite No.	title of the item (book, mag			(in CAPITAL LETTERS), title of the article (when appropriate), azine, journal, serial, symposium, catalog, etc.), date, page(s), ber(s), publisher, city and/or country where published.							
Dai 08 200) E		Miguel PUERTAS-MEJIA, et al., "In vitro radical scavenging activity of essential oils from Columbian plants and fractions from oregano (Origanum vulgare L.) essential oil, Flavour and Fragrance Journal, J. 2002, Vol. 17, No. 5, pp. 380-384.										
THE PROPERTY			J. JIMÉNEZ et al., "Thymus zygis oil: Its effects on CCIs-induced hepatotoxicity and free radical scavenger activity," J. Essent. Oil Res., Vol. 5, pp. 153-158 (Mar/Apr 1993)										
			tygenase inhibitors 2,6-di- <i>tert</i> -butylphenol b. 4207-4216 (Sep. 2003)										
			Y. AZUMA et al., "Pharmacological studies on the anti-flammatory action of phenolic compounds," J Dent Res, Vol. 65, No. 1, pp. 53-56 (Jan. 1986)										
					-								

Date

Considered

Examiner

Signature

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.